ScholarIQanswers from OpenAlex

Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers

PaperCitations, authors & open-access status

Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers have?

ScholarIQcitation count

Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers has 365 citations in the OpenAlex counts ScholarIQ stores.

When was Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers published?

ScholarIQyear

Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers has 2015 year in the ScholarIQ index.

What is the open-access status of Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers?

ScholarIQoa status

Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers has green oa status in the ScholarIQ index.

What is the DOI of Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers?

ScholarIQdoi

The DOI for Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers is on the source record.

What is the PMID of Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers?

ScholarIQpmid

The PMID for Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers is on the source record.

What is the OpenAlex record for Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers?

ScholarIQopenalex

The OpenAlex for Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial